216 related articles for article (PubMed ID: 6543245)
1. Cytidine(5')diphosphocholine enhances the ability of haloperidol to increase dopamine metabolites in the striatum of the rat and to diminish stereotyped behavior induced by apomorphine.
Agut J; Coviella IL; Wurtman RJ
Neuropharmacology; 1984 Dec; 23(12A):1403-6. PubMed ID: 6543245
[TBL] [Abstract][Full Text] [Related]
2. Effects of hypoxia and cytidine (5') diphosphocholine on the concentrations of dopamine, norepinephrine and metabolites in rat hypothalamus and striatum.
Saligaut C; Daoust M; Moore N; Boismare F
Arch Int Pharmacodyn Ther; 1987 Jan; 285(1):25-33. PubMed ID: 3579424
[TBL] [Abstract][Full Text] [Related]
3. Cytidine (5')diphosphocholine modulates dopamine K(+)-evoked release in striatum measured by microdialysis.
Agut J; Ortiz JA; Wurtman RJ
Ann N Y Acad Sci; 2000; 920():332-5. PubMed ID: 11193174
[TBL] [Abstract][Full Text] [Related]
4. Developmental change in striatal concentration of homovanillic acid and 3,4-dihydroxyphenylacetic acid in response to apomorphine and haloperidol treatment.
Nomura Y; Komori T; Okuda S; Segawa T
Arch Int Pharmacodyn Ther; 1979 Jan; 237(1):25-30. PubMed ID: 485682
[TBL] [Abstract][Full Text] [Related]
5. Choline and physostigmine enhance haloperidol-induced HVA and DOPAC accumulation.
Millington WR; Wurtman RJ
Eur J Pharmacol; 1982 Jun; 80(4):431-4. PubMed ID: 7106193
[TBL] [Abstract][Full Text] [Related]
6. Apomorphine-haloperidol interactions: different types of antagonism in cortical and subcortical brain regions.
Bacopoulos NG; Roth RH
Brain Res; 1981 Feb; 205(2):313-9. PubMed ID: 7470869
[TBL] [Abstract][Full Text] [Related]
7. Tolerance phenomena with neuroleptics catalepsy, apomorphine stereotypies and striatal dopamine metabolism in the rat after single and repeated administration of loxapine and haloperidol.
Asper H; Baggiolini M; Burki HR; Lauener H; Ruch W; Stille G
Eur J Pharmacol; 1973 Jun; 22(3):287-94. PubMed ID: 4738903
[No Abstract] [Full Text] [Related]
8. Behavioural and biochemical alterations in the function of dopamine receptors following repeated administration of L-DOPA to rats.
Hall MD; Cooper DR; Fleminger S; Rupniak NM; Jenner P; Marsden CD
Neuropharmacology; 1984 May; 23(5):545-53. PubMed ID: 6539859
[TBL] [Abstract][Full Text] [Related]
9. Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation.
Carvey PM; Hitri A; Goetz CG; Tanner CM; Klawans HL
Life Sci; 1988; 42(22):2207-15. PubMed ID: 3374255
[TBL] [Abstract][Full Text] [Related]
10. Haloperidol inhibits the disappearance of acidic dopamine metabolites from rat striatum.
Moleman P; Bruinvels J; van Valkenburg CF
J Pharm Pharmacol; 1978 Sep; 30(9):583-5. PubMed ID: 29101
[No Abstract] [Full Text] [Related]
11. The release of endogenous dopamine and its metabolites from rat striatum as detected in push-pull perfusates: effects of systematically administered drugs.
Radhakishun FS; Korf J; Venema K; Westerink BH
Pharm Weekbl Sci; 1983 Aug; 5(4):153-8. PubMed ID: 6622209
[TBL] [Abstract][Full Text] [Related]
12. Effects of CDP-choline on striatal dopamine level and behavior in rats.
Shibuya M; Kageyama N; Taniguchi T; Hidaka H; Fujiwara M
Jpn J Pharmacol; 1981 Feb; 31(1):47-52. PubMed ID: 7253343
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of haloperidol-induced increase in rat striatal or mesolimbic 3,4-dihydroxyphenylacetic acid and homovanillic acid by pretreatment with chronic methamphetamine.
Toru M; Mataga N; Takashima M; Nishikawa T
Psychopharmacology (Berl); 1981; 74(4):316-20. PubMed ID: 6794073
[TBL] [Abstract][Full Text] [Related]
14. Effects of apomorphine on in vivo release of dopamine and its metabolites in the prefrontal cortex and the striatum, studied by a microdialysis method.
Ozaki N; Nakahara D; Miura H; Kasahara Y; Nagatsu T
J Neurochem; 1989 Dec; 53(6):1861-4. PubMed ID: 2809596
[TBL] [Abstract][Full Text] [Related]
15. Development of haloperidol-induced dopamine release in the rat striatum using intracerebral dialysis.
Walters DE; Chapman CD; Howard SG
J Neurochem; 1990 Jan; 54(1):181-6. PubMed ID: 2293609
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the synthesis and metabolism of striatal dopamine after disruption of nerve conduction in the medial forebrain bundle.
Commissiong JW; Slimovitch C; Toffano G
Br J Pharmacol; 1990 Apr; 99(4):741-9. PubMed ID: 2361171
[TBL] [Abstract][Full Text] [Related]
17. Circling behaviour in rats with unilateral lesions of the nigrostriatum induced by 6-hydroxydopamine: changes induced by oral administration of cytidine-5'-diphosphocholine.
Saligaut C; Daoust M; Moore N; Boismare F
Neuropharmacology; 1987 Sep; 26(9):1315-9. PubMed ID: 3118233
[TBL] [Abstract][Full Text] [Related]
18. Effects of neurotransmitters or drugs on the in vivo release of dopamine and its metabolites.
Kito S; Shimoyama M; Arakawa R
Jpn J Pharmacol; 1986 Jan; 40(1):57-67. PubMed ID: 2870204
[TBL] [Abstract][Full Text] [Related]
19. Apomorphine-induced stereotyped biting in the tortoise in relation to dopaminergic mechanisms.
Andersen H; Braestrup C; Randrup A
Brain Behav Evol; 1975; 11(5-6):365-73. PubMed ID: 1238150
[TBL] [Abstract][Full Text] [Related]
20. Striatal dopamine receptor sensitivity after subchronic fencamfamine in the rat.
Scavone C; De Lucia R; Bernardi MM; Aizenstein ML
Eur J Pharmacol; 1985 May; 112(1):11-6. PubMed ID: 4040467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
